Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by ProLynx Inc.
ProLynx announces preclinical results of long-acting semaglutide requiring once monthly dosing
August 21, 2024
From
ProLynx Inc.
Via
GlobeNewswire
ProLynx announces initiation of the Phase II Topology clinical trial of its DNA-damaging agent PLX038 in triple-negative breast cancer at the Institut Curie
March 25, 2024
From
ProLynx Inc.
Via
GlobeNewswire
ProLynx announces initiation of Phase I/II clinical trial of its DNA-damaging agent PLX038 in patients with rare CNS tumors at the National Cancer Institute (NCI)
February 05, 2024
From
ProLynx Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.